Semax is a synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro) developed in Russia in the 1980s. It is derived from a fragment of adrenocorticotropic hormone (ACTH 4-10) but modified to remove hormonal activity. Semax has been studied for nootropic, neuroprotective, and neuroregenerative properties. It is approved for medical use in Russia and Ukraine for conditions such as ischemic stroke, memory impairment, and cognitive decline, but remains experimental and is not FDA-approved in the United States.
How It Is Used in Research Settings
- Investigated for cognitive enhancement and memory support in preclinical and human studies.
- Studied for neuroprotection and recovery in ischemic stroke and traumatic brain injury models.
- Explored for modulating brain-derived neurotrophic factor (BDNF) and neuroplasticity pathways.
- Examined for potential effects on anxiety, depression, and stress adaptation.
Proposed Uses (Research Areas)
- Nootropic and cognitive function studies.
- Stroke recovery and neuroprotection research.
- Traumatic brain injury models.
- Neurodegenerative disease research (Alzheimer’s, Parkinson’s).
- Mood and stress resilience studies.
How It Is Dosed in Research Settings
- Intranasal: The most common route; studied at 200–1,200 mcg per day, divided into 2–3 doses.
- Injectable: Less commonly studied; doses typically 300–600 mcg per day subcutaneously.
- Cycle length: Research protocols vary from short-term (5–14 days for stroke recovery) to longer cognitive studies lasting weeks to months.
- Handling: Supplied as solution or lyophilized powder; stored refrigerated and protected from light.
Important Considerations
- Regulatory status: Approved in Russia and Ukraine for certain medical uses, but not FDA-approved in the U.S. or most Western countries.
- Evidence base: Clinical studies in Eastern Europe support cognitive and neuroprotective effects; Western validation is limited.
- Safety: Generally well tolerated in research, with few reported side effects (occasional mild headache, anxiety, or irritability). Long-term data is limited.
Disclaimer
This material is provided for educational purposes only and summarizes published research on Semax.
It is not medical advice. Semax is experimental, not FDA-approved in the United States, and should not be viewed as a therapy for medical use.
This peptide is for research use only.